Multidrug-resistant acinetobacter - A challenge for public health;Acinetobacter multirresistente - Um desafio para a saúde pública

Scientia Medica

Volumn 23, Issue 1, 2013, Pages 56-62

  Martins, Andreza Francisco ^a,b   Barth, Afonso Luís ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Secretaria Municipal da Saude   (Brazil)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acinetobacter; Antibiotic resistance bacterial; Cross infection; Infection control; Multidrug resistance; Outbreaks prevention and control; Pneumonia ventilator associated; Risk factors

Indexed keywords

CARBAPENEM; CARBAPENEMASE; METALLO BETA LACTAMASE; PORIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ARTICLE; BACTEREMIA; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; DISEASE ASSOCIATION; DRUG CHOICE; ENZYME SYNTHESIS; EPIDEMIC; HOSPITAL INFECTION; INFECTION CONTROL; INFECTION RATE; INFECTION RISK; INTENSIVE CARE UNIT; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; PUBLIC HEALTH PROBLEM; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84876790363     PISSN: 18065562     EISSN: 19806108     Source Type: Journal    
DOI: 10.15448/1980-6108.2013.1.12563     Document Type: Article

References (46)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-82.
2. Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol. 1991;29(2):277-82.
3. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents. 2008;32(2):106-19.
4. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12(9):826-36.
5. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939-51.
6. Bernards AT, Harinck HI, Dijkshoorn L, et al. Persistent Acinetobacter baumannii? Look inside your medical equip-ment. Infect Control Hosp Epidemiol. 2004;25(11): 1002-4.
7. Lee HW, Koh YM, Kim J, et al. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect. 2008;14(1):49-54.
8. Rodriguez-Bano J, Marti S, Soto S, et al. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin Microbiol Infect. 2008;14(3):276-8.
9. Falagas ME, Karveli EA, Kelesidis I, et al. Community-acquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis. 2007;26(12):857-68.
10. Lima AL, Oliveira PR, Paula AP. Acinetobacter infection. N Engl J Med. 2008;358(26):2846-7.
11. Baran G, Erbay A, Bodur H, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12(1):16-21.
12. Davis KA, Moran KA, McAllister CK, et al. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis. 2005;11(8):1218-24.
13. Turton JF, Kaufmann ME, Gill MJ, et al. Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict. J Clin Microbiol. 2006;44(7):2630-4.
14. Kennedy PJ, Haertsch PA, Maitz PK. The Bali burn disaster: implications and lessons learned. J Burn Care Rehabil. 2005;26(2):125-31.
15. Mak JK, Kim MJ, Pham J, et al. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2009;63(1):47-54.
16. Lee NY, Lee HC, Ko NY, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28(6):713-9.
17. Asensio A, Canton R, Vaque J, et al. Prevalence of infection by carbapenem- Acinetobacter baumannii in Spain (1999-2005). Enferm Infecc Microbiol Clin. 2008;26(4):199-204.
18. Falagas ME, Bliziotis IA, Siempos, II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10(2):48.
19. Abbo A, Carmeli Y, Navon-Venezia S, et al. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007;26(11): 793-800.
20. Maragakis LL, Perl, TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254-63.
21. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751-62.
22. Van den Broek PJ, Arends J, Bernards AT, et al. Epidemiology of multiple Acinetobacter outbreaks in The Netherlands during the period 1999-2001. Clin Microbiol Infect. 2006;12(9):837-43.
23. Wang SH, Sheng WH, Chang YY, et al. Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J Hosp Infect. 2003;53(2):97-102.
24. Levin AS, Gobara S, Mendes CM, et al. Environmental contamination by multidrug-resistant Acinetobacter baumannii in an intensive care unit. Infect Control Hosp Epidemiol. 2001;22(11):717-20.
25. Enoch DA, Summers C, Brown NM, et al. Investigation and management of an outbreak of multidrug-carbapenem-resistant Acinetobacter baumannii in Cambridge, UK. J Hosp Infect. 2008;70(2):109-18.
26. Furtado GH, Martins ST, Machado AM, et al. Clinical culture surveillance of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in Sao Paulo, Brazil: a 7-year study. Infect Control Hosp Epidemiol. 2006;27(11):1270-3.
27. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42(5):692-9.
28. Dalla-Costa LM, Coelho JM, Souza HA, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol. 2003;41(7):3403-6.
29. Carvalho KR, Carvalho-Assef AP, Peirano G, et al. Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents. 2009;34(1):25-8.
30. Martins AF, Kuchenbecker R, Sukiennik T, et al. Carbapenem-Resistant Acinetobacter baumannii Producing the OXA-23 Enzyme: Dissemination in Southern Brazil. Infect. 2009;37(5):474-6.
31. Coelho JM, Turton JF, Kaufmann ME, et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol. 2006;44(10):3623-27.
32. Valenzuela JK, Thomas L, Partridge SR, van der Reijden T, Dijkshoorn L, Iredell J. Horizontal gene transfer in a polyclonal outbreak of carbapenem-resistant Acinetobacter baumannii. J Clin Microbiol. 2007;45(2):453-60.
33. Bou G, Cervero G, Dominguez MA, Quereda C, et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol. 2000;38(9): 3299-3305.
34. Nemec A, Krizova L, Maixnerova M, et al. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II. J Antimicrob Chemother. 2008;62(3):484-9.
35. van Dessel H, Dijkshoorn L, van der Reijden T, et al. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol. 2004;155(2):105-12.
36. Longo B, Pantosti A, Luzzi I, et al. Molecular findings and antibiotic-resistance in an outbreak of Acinetobacter baumannii in an intensive care unit. Ann Ist Super Sanita. 2007;43(1):83-8.
37. Zarrilli R, Casillo R, Di Popolo A, et al. Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy. Clin Microbiol Infect. 2007;13(5):481-9.
38. Chuang YY, Huang YC, Lin CH, et al. Epidemiological investigation after hospitalising a case with pandrug-resistant Acinetobacter baumannii infection. J Hosp Infect. 2009;72(1):30-5.
39. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY. the preantibiotic era has returned. Arch Intern Med. 2002;162(13):1515-20.
40. Morgan DJ, Weisenberg SA, Augenbraun MH, et al. Multidrug-resistant Acinetobacter baumannii in New York City - 10 years into the epidemic. Infect Control Hosp Epidemiol. 2009;30(2):196-7.
41. Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000;31(1): 101-6.
42. Jones RN, Deshpande L, Fritsche TR, et al. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). Diagn Microbiol Infect Dis. 2004;49(3):211-6.
43. Lolans K, Rice TW, Munoz-Price LS, et al. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother. 2006;50(9):2941-5.
44. Martins AF, Kuchenbecker RS, Pilger KO, et al. High endemic levels of multidrug-resistant Acinetobacter baumannii among hospitals in southern Brazil. Am J Infect Control 2012; 40(2):108-12.
45. Hanlon GW. The emergence of multidrug resistant Acinetobacter species: a major concern in the hospital setting. Lett Appl Microbiol. 2005;41(5):375-8.
46. Marchaim D, Navon-Venezia S, Schwartz D, et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol. 2007;45(5):1551-5.